Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000645752
Ethics application status
Not yet submitted
Date submitted
28/05/2013
Date registered
7/06/2013
Date last updated
7/06/2013
Type of registration
Prospectively registered

Titles & IDs
Public title
Laser doppler flowmetry in anaesthetic allergy skin testing
Scientific title
Laser doppler flowmetry versus conventional skin prick testing in anaesthetic allergy skin testing in patients over the age of 18 referred to allergy clinic with suspected anaphylaxis.
Secondary ID [1] 282561 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anaphylaxis (antibody mediated allergic reaction) 289228 0
Anaphylactoid (non antibody mediated) allergic reaction 289229 0
Condition category
Condition code
Anaesthesiology 289562 289562 0 0
Other anaesthesiology
Inflammatory and Immune System 289563 289563 0 0
Allergies

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Laser Doppler flowmetry (LDF) is an inexpensive, non-invasive method of measuring the blood flow in the small vessels of the skin. In allergic patients, following skin testing the small blood vessels in the skin open and blood flow increases. This can be detected by LDF in a manner that is more objective.

The laser used in LDF is a Moor FLPI-2. It is classified as a “class 1” laser. The product information states it is “safe to use without eye protection”. The Monash University OHS website states that class 1 lasers “…are safe under most circumstances and are incapable of damaging the eyes or skin because of either engineered design or inherently low power output”.

The study will involve testing concurrently, at the same site, conventional skin testing and LDF testing.

Conventional skin testing will be undertaken to the drugs that the patient was exposed to perioperatively that could have been potential causal agents for allergy. Therefore the drugs tested will be specific to each individual case and we cannot predict what drugs will be skin tested as that depends on what drugs were administered during the anaesthetic.

Our testing involves intradermal administration of all the drugs that were given. Intradermal testing involves giving 0.02ml of dilute drug into the dermis of the skin. The dilutions vary depending on the drug from 1:100 to 1:100 000. That equates to about one millionth of the dose of the drug that was administered in the anaesthetic. We also do a positive control - that is a skin prick test (much <0.02mL) of 8mg/ml histamine.

Here is a list of drugs that may be required to be tested:

Drug Dilution Original concentration
Alfentanil 100 0.5 mg/mL
Amoxicillin 100 100 mg/mL
Atracurium 10,000 10 mg/mL
Atropine 1,000 600 mcg/mL
Bupivacaine 100 2.5 mg/mL (0.25%)
Cephazolin 100 100 mg/mL
Chlorhexidine 1,000 0.20%
Cisatracurium 1,000 2 mg/mL
Clindamycin 100 150mg/mL
Codeine 1,000 50 mg/mL
Dexamethasone 100 4mg/mL
Diazepam 100 5 mg/mL
Diclofenac 1,000 75 mg/mL
Droperidol 1,000 5 mg/mL
Erythromycin 1,000 50mg/mL
Fentanyl 100 50 mcg/mL
Gelofusine 100
Gentamicin 100 40 mg/mL
Glycopyrolate 100 200 mcg/mL
Granisetron 1000 1 mg/mL
Iodine 100 5% (Half)
Ketamine 100 20 mg/mL
Lignocaine 100 10 mg/mL (1%)
Metoclopromide 1,000 5 mg/mL
Midazolam 20 1 mg/mL
Mivacurium 1,000 2 mg/mL
Morphine 100,000 10 mg/mL
Neostigmine 1,000 2.5 mg/mL
Ondansetron 1000 2 mg/mL
Pancuronium 1,000 2 mg/mL
Paracetamol 100 10 mg/mL
Parecoxib 1,000 10 mg/mL
Patent blue 100 Half strength
Pethidine 100,000 50 mg/mL
Prilocaine 100 10 mg/mL (1%)
Propofol 100 10 mg/mL
Protamine 1,000 50 mg/mL
Remifentanil 1,000 0.5 mg/mL
Rocuronium 1,000 10 mg/mL
Ropivacaine 100 2 mg/mL (0.2%)
Suxamethonium1,000 50 mg/mL
Thiopentone 100 25 mg/mL
Tropisetron 100 1 mg/mL
Vancomycin 10,000 50 mg/mL
Vecuronium 1,000 4 mg/mL

One clinician will inject all the drugs to be tested into the skin at the same time as per conventional skin testing protocols. At 20 minutes after skin injection, a second clinician will assess the patient’s test site, again, using conventional skin testing protocols. The LDF testing will be recorded by the first clinician and stored on a password protected, specifically assigned computer.

At another time (to allow blinding) the second clinician will assess the LDF results.

The conclusions made using both assessment methods will be compared.
Intervention code [1] 287225 0
Diagnosis / Prognosis
Comparator / control treatment
LDF is compared to conventional skin prick testing which is the gold standard test for identification of anaesthetic agents that a patient is allergic to. This currently involves injecting diluted drug into the skin and measuring the swelling (wheal) and redness (flare) that has developed after 20 minutes. The clinician makes these measurements with a device such as a ruler or callipers
Control group
Active

Outcomes
Primary outcome [1] 289657 0
Comparable positive or negative test result by LDF to the conventional skin testing method.
Timepoint [1] 289657 0
At 20minutes following injection of diluted drug, measured concurrently (by LDF device) with conventional skin testing (by clinician).
Secondary outcome [1] 302963 0
Nil
Timepoint [1] 302963 0
Nil

Eligibility
Key inclusion criteria
All patients scheduled for anaesthetic allergy testing at Sir Charles Gairdner Hospital.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Unable to give informed consent
Aged less than 18 years
Pregnant women
Patient refusal

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All patients referred to allergy clinic at Sir Charles Gairdner Hospital that have consented and do not satisfy any of the exclusion criteria will have the intervention (LDF).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/07/2013
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 1053 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 6913 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 287343 0
Self funded/Unfunded
Name [1] 287343 0
Nil funding required.
Country [1] 287343 0
Primary sponsor type
Individual
Name
Dr Russell Clarke
Address
Anaesthesia Department, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Western Australia 6009
Country
Australia
Secondary sponsor category [1] 286114 0
None
Name [1] 286114 0
Address [1] 286114 0
Country [1] 286114 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 289331 0
Sir Charles Gairdner Hospital Group Human Research Ethics Committee
Ethics committee address [1] 289331 0
Ethics committee country [1] 289331 0
Australia
Date submitted for ethics approval [1] 289331 0
03/06/2013
Approval date [1] 289331 0
Ethics approval number [1] 289331 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 40286 0
Dr Russell Clarke
Address 40286 0
Anaesthetic department, Sir Charles Gairdner Hospital, Hospital Avenue Nedlands, Western Australia 6009
Country 40286 0
Australia
Phone 40286 0
+61412 288 818
Fax 40286 0
+61 8 9346 4375
Email 40286 0
russellclarke@outlook.com
Contact person for public queries
Name 40287 0
Russell Clarke
Address 40287 0
Anaesthetic department, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Western Australia 6009
Country 40287 0
Australia
Phone 40287 0
+61412 288 818
Fax 40287 0
+61 8 9346 4375
Email 40287 0
russellclarke@outlook.com
Contact person for scientific queries
Name 40288 0
Russell Clarke
Address 40288 0
Anaesthetic department, Sir Charles Gairdner Hospital, Hospital Avenue Nedlands, Western Australia 6009
Country 40288 0
Australia
Phone 40288 0
+61412 288 818
Fax 40288 0
+61 8 9346 4375
Email 40288 0
russellclarke@outlook.com

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.